Physician

Rajat Maheshwari, M.D.

According to 2025 Medicare claims, Rajat Maheshwari, M.D. (NPI: 1346479458) practices nephrology in the Akron, OH market, with the plurality of this provider's patient population coming from Summit, OH. This provider's primary affiliated billing organization is PREMIER RENAL CARE ASSOCIATES LLC (NPI: 1326780719; TIN: 880655493) and primary practice location at 44221-3227.

Maheshwari's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 387 traditional Medicare patients, billed 4,001 HCPCS/CPT codes, and received $212,179 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 3,031 prescription claims across 485 beneficiaries totaling $902,038 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2018 DME data shows 17 claims. Open Payments data shows 71 records totaling $1,555. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $34,408 to $212,179. Similarly, Part D prescription costs have moved sharply higher in recent years, from $15,007 to $902,038. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	165	476	$34,408
2016	N/R	N/R	N/R
2017	152	398	$33,847
2018	446	1,707	$158,654
2019	437	1,501	$132,941
2020	510	1,763	$167,384
2021	478	1,580	$161,579
2022	400	1,135	$118,676
2023	380	3,566	$208,553
2024	387	4,001	$212,179

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	61	225	$15,007
2016	21	51	$1,389
2017	76	215	$24,485
2018	225	1,289	$141,064
2019	251	1,500	$183,745
2020	302	1,793	$326,084
2021	338	1,961	$511,066
2022	428	2,320	$652,397
2023	477	2,890	$1,081,126
2024	485	3,031	$902,038

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	37	$3,338
2016	N/R	12	$51
2017	N/R	N/R	N/R
2018	N/R	17	$226
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	78	88	$131
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	87	179	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	179	370	$87
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	122	216	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	200	405	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	235	13,455	$243,191
Jardiance	Empagliflozin	189	11,165	$217,459
Kerendia	Finerenone	83	5,820	$119,796
Tolvaptan	Tolvaptan	12	360	$52,180
Lokelma	Sodium Zirconium Cyclosilicate	23	1,470	$50,139

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	71	$1,555	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rajat Maheshwari, M.D.?

Tedicare shows public-source Medicare data for Rajat Maheshwari, M.D. (NPI 1346479458), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rajat Maheshwari, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rajat Maheshwari, M.D.?

Rajat Maheshwari, M.D. is linked to PREMIER RENAL CARE ASSOCIATES LLC (billing NPI 1326780719) in the available physician profile data.

Does Rajat Maheshwari, M.D. have Open Payments data?

Rajat Maheshwari, M.D. has 71 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.